205 related articles for article (PubMed ID: 19182828)
1. Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
Hunter P
EMBO Rep; 2009 Feb; 10(2):125-8. PubMed ID: 19182828
[No Abstract] [Full Text] [Related]
2. Focusing on boron in medicinal chemistry.
Ramachandran PV
Future Med Chem; 2013 Apr; 5(6):611-2. PubMed ID: 23617421
[No Abstract] [Full Text] [Related]
3. Drugs: More shots on target.
Appel A
Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
[No Abstract] [Full Text] [Related]
4. Boron chemicals in diagnosis and therapeutics.
Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
[TBL] [Abstract][Full Text] [Related]
5. From orbital hybridization to chemotherapeutics neutralization.
Ghosh N; Emadi A
Blood; 2009 Jun; 113(24):6262. PubMed ID: 19520822
[No Abstract] [Full Text] [Related]
6. Fold up or perish: unfolded protein response and chemotherapy.
Strasser A; Puthalakath H
Cell Death Differ; 2008 Feb; 15(2):223-5. PubMed ID: 18049478
[No Abstract] [Full Text] [Related]
7. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
[No Abstract] [Full Text] [Related]
8. [Pharmacological and clinical profile of Bortezomib (Velcade)].
Fujii H; Kotobuki Y; Nomura S; Harada Y
Nihon Yakurigaku Zasshi; 2007 Nov; 130(5):421-9. PubMed ID: 18000359
[No Abstract] [Full Text] [Related]
9. Productively combining proteasome inhibition with the immunotherapy of cancer.
Sayers T
J Mol Med (Berl); 2008 Aug; 86(8):857-60. PubMed ID: 18612622
[No Abstract] [Full Text] [Related]
10. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
11. Boron in cancer therapeutics: An overview.
Kulkarni S; Bhandary D; Singh Y; Monga V; Thareja S
Pharmacol Ther; 2023 Nov; 251():108548. PubMed ID: 37858628
[TBL] [Abstract][Full Text] [Related]
12. New approach to incorporation of boron in tumor-seeking molecules.
Sivaev IB; Semioshkin AA; Bregadze VI
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S91-3. PubMed ID: 19375335
[TBL] [Abstract][Full Text] [Related]
13. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
14. Boron tracedrugs challenge for neutron dynamic therapy.
Hori H; Uto Y; Nakata E
Anticancer Res; 2012 Jun; 32(6):2235-9. PubMed ID: 22641657
[TBL] [Abstract][Full Text] [Related]
15. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
16. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
Bold R
Cancer Invest; 2004; 22(2):328-9. PubMed ID: 15199617
[No Abstract] [Full Text] [Related]
17. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
18. Application of cycloaddition reactions to the syntheses of novel boron compounds.
Zhu Y; Siwei X; Maguire JA; Hosmane NS
Molecules; 2010 Dec; 15(12):9437-49. PubMed ID: 21178899
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
20. Proteasome inhibitors in cancer therapy.
Testa U
Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
